← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
SR ONE CAPITAL MANAGEMENT, LLC
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001853723
Purchase history
- Companies traded
- 4
- Purchases · 12M
- 3
- Purchases · 24M
- 4
- Average purchase
- $9.9M
- Median purchase
- $10.0M
- Gross purchase value
- $39.5M
Companies: ADARx Pharmaceuticals, Inc. | Avalyn Pharma Inc. | Odyssey Therapeutics, Inc. | Zenas BioPharma, Inc.
4 SEC accession(s) · 3 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-29 | ADARx Pharmaceuticals, Inc. | ADRX | 10% Owner | $17.1M | Open filing |
| 2026-05-11 | Odyssey Therapeutics, Inc. | ODTX | 10% Owner | $10.0M | Open filing |
| 2026-05-01 | Avalyn Pharma Inc. | AVLN | 10% Owner | $10.0M | Open filing |
| 2025-10-14 | Zenas BioPharma, Inc. | ZBIO | 10% Owner | $2.4M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small Sample | 75.0% (3/4) | 0.0% (0/3) | -10.8% | -7.7% | -11.9% |
| 20D | 2Small Sample | 66.7% (2/3) | 0.0% (0/2) | -8.8% | -8.8% | -15.9% |
| 60D | 2Small Sample | 66.7% (2/3) | 50.0% (1/2) | +6.0% | +6.0% | -7.3% |
| 120D | 0No Data | 0.0% (0/1) | — | — | — | — |
Research patterns
- First purchase in 12M
- 3/3
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 4/4
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.